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Post-translational modiﬁcationa b s t r a c t
Recently, we disclosed that KIAA1199-mediated hyaluronan (HA) depolymerization requires an
acidic cellular microenvironment (e.g. clathrin-coated vesicles or early endosomes), but no informa-
tion about the structural basis underlying the cellular targeting and functional modiﬁcation of
KIAA1199 was available. Here, we show that the cleavage of N-terminal 30 amino acids occurs in
functionally matured KIAA1199, and the deletion of the N-terminal portion results in altered intra-
cellular trafﬁcking of the molecule and loss of cellular HA depolymerization. These results suggest
that the N-terminal portion of KIAA1199 functions as a cleavable signal sequence required for
proper KIAA1199 translocation and KIAA1199-mediated HA depolymerization.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hyaluronan (HA) is a high molecular weight, non-sulfated gly-
cosaminoglycan component of the extracellular matrix present in
many tissues, such as skin, cartilage, and other connective tissues,
providing structural and functional integrity to the organs. HA is
rapidly depolymerized under physiological conditions from ex-
tra-large native molecules to intermediate-size fragments in the
extracellular milieu [1]. HA degradation is enhanced under certain
pathological conditions, and its lower-molecular-weight products
are commonly detected in diseases such as arthritis and cancers
[2,3]. Two hyaluronidases HYAL1 and HYAL2 and cell surface HA
receptor CD44 were reported to play key roles in HA degradation
[4,5]. However, we have recently shown that KIAA1199 is essential
for endogenous HA degradation in human skin ﬁbroblasts and that
transfection of KIAA1199 cDNA into cells confers on them the abil-
ity to catabolize HA via the clathrin-coated pit pathway [6]. Inaddition, KIAA1199 was expressed by dermal ﬁbroblasts in normal
skin and over-expressed by synovial ﬁbroblasts and tissues from
arthritic joints [6]. All these data suggest that KIAA1199 plays a
key role in HA catabolism under certain physiological and patho-
logical conditions.
KIAA1199 contains a predicted 4083 bp ORF encoding a protein
with a molecular weight of 153 kDa (1361 amino acids) (Fig. 1A)
[7], which is composed of four PbH1 domains, consisting of parallel
b-helix repeats, believed to be involved in polysaccharide hydroly-
sis; one G8 domain, containing eight conserved glycine residues
and consisting of ﬁve b-strand pairs and one a-helix, expected to
take part in extracellular ligand binding; two GG domains, consist-
ing of seven b-strands and two a-helices, of no predicted function;
and seven predicted N-glycosylation sites [8–10]. And, the
N-terminal portion of 30 amino acids is predicted to be a cleavable
signal sequence for ER (endoplasmic reticulum) targeting [7]. Our
previous study has demonstrated that two mutations at the
Arg187 residue (R187C and R187H) located in one of the GG
domains result in loss of HA depolymerization [6]. All these data
suggest that the GG, G8 and PbH1 domains are responsible for
KIAA1199-mediated binding and depolymerization of HA. We have
also shown that KIAA1199 is localized close to the clathrin heavy
chain in some vesicles in the periphery of KIAA1199-expressing
cells, and thus an acidic, dynamic and energy-coupling microenvi-
ronment may be crucial for KIAA1199-mediated HA depolymeriza-
tion [6]. It has also been shown that KIAA1199 is secreted to
Fig. 1. HA depolymerization by HEK293 cells expressing KIAA1199-V5 and KIAA1199(D30aa)-V5, and N-terminal amino acid sequence of functionally expressed KIAA1199.
(A) The schematic representation of the structure of full-length KIAA1199. Functional domains of KIAA1199 are indicated as follows: SS, predicted N-terminal signal
sequence; PbH1, PbH1 domain; GG, GG domain; G8, G8 domain. The predicted N-glycosylation sites are shown by arrows. Numbers indicate the positions of the residues
relative to the N-terminus of the full length KIAA1199. (B) A schematic diagram showing constructs of KIAA1199-V5 and KIAA1199(D30aa)-V5 used for transfection. V5,
C-terminal V5-epitope tag. Molecular weights of SS and V5 tag are about 3.2 kDa and 3 kDa, respectively. (C) HEK293 cells were transiently transfected with either an empty
vector (Mock) or a vector containing KIAA1199-V5 or KIAA1199(D30aa)-V5 cDNA. The expression of KIAA1199-V5 and KIAA1199(D30aa)-V5 proteins was assessed by
immunoblotting using anti-KIAA1199 and V5 monoclonal antibodies. GAPDH, a loading control. (D) Mock, KIAA1199-V5 and KIAA1199(D30aa)-V5 transfectants were
incubated with [3H]HA for 24 h, and HA depolymerization was then examined by chromatography on a Sepharose CL-2B column. Dotted lines indicate [3H]HA without
incubation. (E) N-terminal amino acid sequence of KIAA1199. The signal sequence cleavage site is shown by an arrow, and the actual N-terminal protein sequence obtained is
underlined.
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However, the structural basis underlying the cellular targeting
and functional modiﬁcation of KIAA1199 to exert cellular HA depo-
lymerization and secretion to extracellular space remains elusive.
In the current study, we investigated post-translational maturation
of KIAA1199 and its possible roles in the functional expression of
the molecule in HA depolymerization, and demonstrated that the
N-terminal 30 amino acid portion of KIAA1199 is the signal
sequence essential for proper translocation of KIAA1199 and
cellular HA depolymerizing activity.
2. Materials and methods
2.1. Preparations of plasmids and transfectants
Expression vectors for KIAA1199 with a C-terminal V5-epitope
(KIAA1199-V5) and its N-terminal truncated form (KIAA1199(-
D30aa)-V5) were constructed by inserting the full length KIAA1199
cDNAs and the N-terminal 30 amino acid-deleted cDNAs for which
the codon of residues of Met1 to Ser30 was replaced by an ATG start
codon into the expression vector pcDNA3.1/V5-His (Invitrogen)
according to the manufacture’s protocol, respectively. The
authenticity of the cDNAs was veriﬁed by sequencing using
Applied Biosystems 3730xl DNA Analyzer (Life Technologies).
Transient transfection was done using Lipofectamine LTX
(Invitrogen), and transfectants were used for the experiments at
48 h after transfection.
2.2. Antibodies
A rat monoclonal antibody against KIAA1199 was previously
developed using a peptide of CA762RYSPHQDADPLKPRE777, which
corresponds to the amino acid residues Ala762 to Glu777 of
KIAA1199 (GenBank accession number NM_018689) [6]. The
mouse anti-V5 antibody was from Invitrogen. The rabbit anti-PDI
and anti-GAPDH antibodies were from Santa Cruz Biotechnology.
The mouse anti-GM130 antibody was from BD Biosciences. The
rabbit anti-TGN46 antibody was from Abcam.2.3. Determination of signal peptide cleavage site of KIAA1199
To prepare cell homogenate supernatants, HEK293 cells
expressing KIAA1199-V5 were lysed in 50 mM Tris–HCl buffer,
pH 8.0 containing 1% Nonidet P-40 and a cocktail of proteinase
inhibitors (Roche Diagnostics), and cleared by centrifugation. Con-
ditioned media were also collected from the cells, and concen-
trated 20-fold with Amicon Ultra-10 kDa NMWL (Millipore).
KIAA1199-V5 in the homogenate supernatants and the conditioned
medium concentrates were immunoprecipitated using Dynal mag-
netic beads protein G (Invitrogen) covered with monoclonal anti-
body against KIAA1199. The beads were washed and then
incubated with NuPAGE LDS sample-loading buffer (Invitrogen)
for 10 min at 70 C. The samples were electrophoresed on NuPAGE
4–12% Bis–Tris gels (Invitrogen) under reducing conditions, and
proteins were transferred onto polyvinylidene diﬂuoride mem-
brane and stained with Coomassie Brilliant Blue. The bands corre-
sponding to KIAA1199 were excised from the membrane for
peptide sequencing. N-terminal amino acids up to the tenth were
determined by standard Edman degradations using a Procise 494
HT Protein Sequencing System (Applied Biosystems).
2.4. Deglycosylation of KIAA1199 with N-glycanase or Endo H
HEK293 cells expressing KIAA1199-V5 or KIAA1199(D30aa)-V5,
and Detroit 551 skin ﬁbroblasts were homogenized in 50 mM
phosphate buffer, pH 7.0, containing a cocktail of proteinase inhib-
itors (Roche Diagnostics) and cleared by centrifugation. Condi-
tioned media were collected from the KIAA1199-V5
transfectants, and concentrated 5-fold with Amicon Ultra-10 kDa
NMWL (Millipore). For N-glycanase digestion, the homogenate
supernatants and the conditioned medium concentrates were
boiled in the presence of 0.1% SDS and 50 mM b-mercaptoethanol
for 5 min, and then incubated with 0.1 U/ml N-glycanase (Glyko)
for 20 h at 37 C according to the manufacturer’s protocol. In the
case of Endo H, samples were boiled in the presence of 0.5% SDS
and 40 mM DTT for 10 min, and then incubated with 25000 U/ml
Endo H (New England BioLabs) according to the manufacturer’s
H. Yoshida et al. / FEBS Letters 588 (2014) 111–116 113protocol. The samples were electrophoresed on NuPAGE 6% Tris–
glycine gels (Invitrogen) and immunoblotted with anti-KIAA1199
monoclonal antibody.2.5. Immunoﬂuorescence microscopy of KIAA1199-V5 and
KIAA1199(D30aa)-V5 in HEK293 cells
For double immunostaining of KIAA1199 or V5-epitope and
Golgi markers (GM130 and TGN46) or ER marker (PDI), HEK293
cells expressing KIAA1199-V5, KIAA1199(D30aa)-V5 were grown
on glass multi-chamber slides (BD Biosciences) to 70–80% conﬂu-
ence, and ﬁxed with 4% (wt/vol) paraformaldehyde in PBS. After
washing in PBS containing 0.05% (vol/vol) Tween 20 (PBS-T), the
cells were reacted with anti-KIAA1199 monoclonal antibody
conjugated to Alexa-Fluor 488 and mouse anti-GM130 antibody
conjugated to Alexa-Fluor 555. The samples were mounted in
VECTASHIELD (Vector). As for controls, samples were reacted with
non-immune IgG conjugated to Alexa-Fluors. These samples were
observed using Zeiss LSM 510 confocal microscope (Carl Zeiss). Sig-
nal intensity line-scan analysis and co-localization analysis were
performed with Zeiss Efﬁcient Navigation software (Carl Zeiss).
2.6. Pulse-chase labeling and immunoprecipitation
HEK293 cells expressing KIAA1199-V5 were preincubated with
Met/Cys-free Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(Sigma) for 1 h, and then pulsed for 30 min with medium contain-
ing [35S]Met (PerkinElmer), then chased for 2, 4, 8 or 24 h with
complete DMEM (Sigma). The treated cells were lysed in 50 mM
Tris–HCl buffer, pH 8.0 containing 1% Nonidet P-40 and a cocktail
of proteinase inhibitors (Roche Diagnostics), and cleared by centri-
fugation. Conditioned media were also collected from the cells, and
concentrated 10-fold. KIAA1199-V5 in the homogenate superna-
tants and conditioned medium concentrates was immunoprecipi-
tated with monoclonal antibody against KIAA1199 as described
above. The beads were washed and then incubated with Tris–
glycine SDS sample buffer (Invitrogen) for 10 min at 70 C. The
samples were analyzed using NuPAGE 6% Tris–glycine gels
(Invitrogen) and autoradiography with the Typhoon Imager (GE
Healthcare).
3. Results and discussion
3.1. Cleavage of N-terminal portion of 30 amino acids occurs in
functionally mature KIAA1199 in HEK293 cells transfected with the
full-length KIAA1199 cDNA
To assess the possible role of N-terminal 30 amino acids of
KIAA1199 in cellular HA depolymerization, HEK293 cells were
transfected with expression vectors encoding the full-length
KIAA1199 with a C-terminal V5-epitope tag (KIAA1199-V5) and
its N-terminally truncated form whose residues of Met1 to Ser30
have been replaced by Met before Thr31 (KIAA1199(D30aa)-V5),
respectively (Fig. 1B). KIAA1199-V5 was detected with an apparent
molecular weight of about 160 kDa by immunoblotting using
anti-KIAA1199 monoclonal antibody, and estimated to be larger
than KIAA1199(D30aa)-V5 by 10 kDa (Fig. 1C). The similar re-
sults were obtained using an antibody against the V5-epitope
(Fig. 1C), indicating that there is no C-terminal processing. We then
examined HA depolymerization by HEK293 cells expressing
KIAA1199-V5 or KIAA1199(D30aa)-V5, and found that KIAA1199-
V5 transfectants degrade exogenous high-molecular-weight [3H]-
labeled HA ([3H]HA) to intermediate size fragments in a similar
manner to normal human skin ﬁbroblasts Detroit 551 cells [6],
whereas mock and KIAA1199(D30aa)-V5 transfectants showednegligible activity (Fig. 1D), suggesting that the expression of
full-length KIAA1199 containing the N-terminal 30 amino acids
is essential for HA depolymerization. In order to verify the predic-
tion that the signal sequence of KIAA1199 is cleaved at the Ser30
and Thr31 bond [7], we performed the N-terminal sequence
analysis of the puriﬁed KIAA1199-V5 protein from cell lysates
of KIAA1199-V5 transfectants by immunoprecipitation with
anti-KIAA1199 monoclonal antibody, and identiﬁed it as
T31VAAGCPDQS (Fig. 1E), indicating that recombinant KIAA1199-
V5 is indeed cleaved between the Ser30 and Thr31 bond. Since
pre-processed KIAA1199-V5 was not observed, N-terminal
processing seems to occur promptly after translation. The size
difference between the two forms is related to differences in
N-glycosylation as described in the next section.
3.2. KIAA1199 is N-glycosylated, and N-terminal 30 amino acids of
KIAA1199 are necessary for proper KIAA1199 translocation
To examine the possibility that mature forms of KIAA1199-V5
and KIAA1199(D30aa)-V5 are glycosylated, both proteins were
treated with N-glycanase or Endo H to remove N-linked oligosac-
charides. After deglycosylation, KIAA1199-V5 protein reduced in
apparent size and located at the position close to KIAA1199(-
D30aa)-V5 by immunoblotting using anti-KIAA1199 antibody
(Fig. 2A). Similar results were observed with endogenous
KIAA1199 in Detroit 551 skin ﬁbroblasts (Fig. 2A). On the other
hand, treatments with N-glycanase or Endo H did not affect the
size of KIAA1199(D30aa)-V5 (Fig. 2A). After concurrent O-glycosi-
dase and neuraminidase treatment, there was no further reduction
in the molecular weights of the N-deglycosylated KIAA1199-V5,
KIAA1199(D30aa)-V5 or endogenous KIAA1199 (data not shown).
Thus, it seems likely that KIAA1199 is N-glycosylated, and the
KIAA1199-V5 protein could be an N-glycosylated form of
KIAA1199(D30aa)-V5. Our earlier study showed that KIAA1199-
mediated HA depolymerization involves a clathrin-coated pit
endocytic pathway, and KIAA1199 is localized in vesicles in periph-
eral regions of KIAA1199-expressing cells [6]. The observation that
KIAA1199(D30aa)-V5 lacked N-glycanase and Endo H-sensitive
N-glycosylation, an ER/early Golgi transportational indicator,
raised the question of whether this construct failed to translocate
to ER/Golgi, leading to a defect in the subsequent transport to
the vesicles in the cell periphery. To address this question, we
examined the subcellular distribution of KIAA1199-V5 and
KIAA1199(D30aa)-V5 in HEK293 cells. By immunocytochemistry
using anti-KIAA1199 antibody, we found that KIAA1199-V5 is con-
centrated at a perinuclear region together with the staining in
some vesicles in the peripheral region (Fig. 2B). Since this perinu-
clear distribution pattern of KIAA1199-V5 seemed consistent with
distribution in the Golgi apparatus, we performed double immuno-
staining of KIAA1199-V5 and GM130 or TGN46 (markers for the
Golgi apparatus), and demonstrated the co-localization, and a
line-scan analysis showed ﬂuorescence intensities of KIAA1199-
V5 and GM130 or TGN46 rising and falling in parallel (Fig. 2B,
KIAA1199-V5 column in top and middle panels). In contrast,
KIAA1199(D30aa)-V5 was localized diffusely throughout the cyto-
plasm without localization in the Golgi area, and a line-scan anal-
ysis revealed that ﬂuorescence intensities of KIAA1199(D30aa)-V5
rise where there are reductions in GM130 or TGN46 intensities
(Fig. 2B, KIAA1199(D30aa)-V5 column in top and middle panels). A
co-localization analysis of KIAA1199-V5 or KIAA1199(D30aa)-V5
with GM130 revealed mild co-localization (35.53% ± 6.34) between
KIAA1199-V5 and GM130, but negligible co-localization (<1%) be-
tween KIAA1199(D30aa)-V5 and GM130 (Supplementary Fig. 1A).
Similar distribution patterns and line-scan proﬁles of KIAA1199-V5
or KIAA1199(D30aa)-V5 and GM130 were obtained with anti-V5
and anti-GM130 antibodies (Fig. 2B, bottom panels). In addition,
Fig. 2. Deglycosylation, cellular localization and HA-binding capability of
KIAA1199-V5 and KIAA1199(D30aa)-V5. (A) Deglycosylation of KIAA1199. The
lysates of KIAA1199-V5 and KIAA1199(D30aa)-V5 transfectants, and Detroit 551
skin ﬁbroblasts were treated with N-glycanase or Endo H, and then subjected to
immunoblotting with anti-KIAA1199 antibody. (B) Double immunostaining of
KIAA1199-V5 or KIAA1199(D30aa)-V5 (green) and Golgi markers (red) with anti-
KIAA1199 or anti-V5 antibodies and anti-GM130 or anti-TGN46 antibodies in
HEK293 cells expressing KIAA1199-V5 or KIAA1199(D30aa)-V5. Line-scans were
taken from the merge column and showed proﬁles of ﬂuorescence intensity against
line distance. N: nucleus; Scale bar: 5 lm. (C) Binding of KIAA1199-V5 and
KIAA1199(D30aa)-V5 to HA. The lysates of HEK293 cells expressing KIAA1199-V5
or KIAA1199(D30aa)-V5 were incubated with H2O (negative control) or HA. The
samples were precipitated with CPC and subjected to immunoblotting with anti-
KIAA1199 antibody.
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PDI antibodies (ER marker), and showed that merged images of
some of the KIAA1199-V5 and PDI were observed in the perinu-
clear region in KIAA1199-V5 transfectants, but were lacking in
KIAA1199(D30aa)-V5 transfectants (Supplementary Fig. 1B). No
ﬂuorescence was observed by non-immune IgG (data not shown).
These results suggest that due to the lack of N-terminal 30 amino
acids, KIAA1199(D30aa)-V5 abolishes the translocation to ERduring protein translation and/or results in a folding defect that
is recognized by the quality control system of the ER, which in turn
results in a defect in a subsequent transportation to the Golgi appa-
ratus and an accumulation of the protein in the cytoplasm. In order
to assess the possible role of N-glycosylation in KIAA1199 function,
we examined the HA-binding activity of KIAA1199-V5 and
KIAA1199(D30aa)-V5. When KIAA1199-V5 and KIAA1199
(D30aa)-V5 proteins isolated from the corresponding transfectants
were incubated with HA and then precipitated with cetylpyridin-
ium chloride (CPC), both proteins were co-precipitated with HA
(Fig. 2C), indicating that both possess the capability to bind to
HA, and therefore suggesting that N-linked oligosaccharides are
unnecessary for HA binding.
3.3. Mature form of KIAA1199 is secreted extracellularly
As previously reported with SW480 cells [10], we also detected
KIAA1199 protein in conditioned media from KIAA1199-V5 trans-
fectants (Fig. 3A) and Detroit 551 skin ﬁbroblasts (Fig. 3B) by
immunoblotting using anti-KIAA1199 or V5 antibodies, but it
was absent in conditioned media from mock and KIAA1199(-
D30aa)-V5 transfectants (Fig. 3A), and KIAA1199 siRNA-treated
skin ﬁbroblasts (Fig. 3B). The treatment of KIAA1199-V5 transfec-
tants with 0–100 lg/ml cycloheximide showed that KIAA1199 pro-
teins in cell lysates and conditioned media decrease dose-
dependently in parallel (Fig. 3C), and pulse-chase experiment using
KIAA1199-V5 transfectants demonstrated that KIAA1199 is not
accumulated intracellularly but observed extracellularly, suggest-
ing that most of KIAA1199 seems to be efﬁciently secreted into
the conditioned medium (Fig. 3C and D). The secreted form of
KIAA1199-V5 in conditioned media was sensitive to N-glycanase
and Endo H (Fig. 3E) and its N-terminal sequence was identiﬁed
as TVAAGCPDQS (Fig. 3F), which are consistent with the results
with KIAA1199-V5 in cell lysate (Fig. 1E and 3E). We also found
that the secreted form of KIAA1199-V5 retains HA-binding capabil-
ity (Fig. 3G). However, [3H]HA was not depolymerized when it was
incubated with conditioned media from KIAA1199-V5 transfec-
tants or Detroit 551 skin ﬁbroblasts at a pH range between 4.0
and 7.0 (data not shown).
The present study is the ﬁrst to investigate the functional mod-
iﬁcation of KIAA1199 molecule. By determining the N-terminal se-
quence and the N-glycanase treatment, we showed that
functionally mature KIAA1199 is indeed cleaved at the Ser30 and
Thr31 bond and N-glycosylated as previously predicted [7,10]. On
the other hand, deletion of the N-terminal 30 amino acids of
KIAA1199 resulted in altered intracellular trafﬁcking and a loss of
N-glycosylation and HA depolymerization without affecting HA-
binding capability. All these ﬁndings provide the evidence that
the N-terminal portion of the pre-processed KIAA1199 is a cleav-
able signal sequence essential in mediating the proper transloca-
tion and the functional expression of KIAA1199 in HA
depolymerization; targeting the molecule to ER and the subse-
quent transport to vesicles in cell periphery via Golgi apparatus,
which are crucial for KIAA1199-mediated HA depolymerization.
Alternatively, we could not exclude the possibility that N-linked
oligosaccharides are directly involved in the degrading activity of
HA, since KIAA1199-mediated HA depolymerizing activity was lost
after KIAA1199 protein was isolated from cells, probably because
the ﬁne conditions for HA degradation could not be reconstituted
in cell lysates [6]. In addition, since we showed that secreted
KIAA1199 has the mature form, and deletion of the N-terminal
30 amino acids of KIAA1199 resulted in a defect in secretion,
KIAA1199 may be secreted from the cells after targeting to ER
and post-translational modiﬁcation. KIAA1199 was previously
identiﬁed in exosomes released from LIM1215 colorectal carci-
noma cells [11], but we found that KIAA1199 secreted from
Fig. 3. Deglycosylation, N-terminal amino acid sequence, and HA-binding capability of KIAA1199 secreted extracellularly. (A) HEK293 cells were transiently transfected with
an empty vector (Mock) or a vector containing KIAA1199-V5 or KIAA1199(D30aa)-V5 cDNA. KIAA1199-V5 and KIAA1199(D30aa)-V5 proteins in the cell lysates and 5-fold
concentrated conditioned media were assessed by immunoblotting using anti-KIAA1199 or anti-V5 monoclonal antibodies. (B) KIAA1199 protein in the cell lysates and 5-fold
concentrated conditioned media from Detroit 551 skin ﬁbroblasts treated with control non-silencing siRNA or targeting siRNA for KIAA1199 were assessed by
immunoblotting using anti-KIAA1199 antibody. (C) Effects of cycloheximide on KIAA1199 secretion. KIAA1199-V5 transfectants were incubated for 24 h in the absence or
presence of 3, 10, 30, 100 lg/ml cycloheximide. KIAA1199 protein in the cell lysates and 10-fold concentrated conditioned media were assessed by immunoblotting using
anti-KIAA1199 antibody. (D) Pulse-chase experiment in KIAA1199-V5 transfectants. Cells were starved for 1 h in Met/Cys free media and then pulse labeled with [35S]Met for
30 min, followed by 2, 4, 8, or 24-h chase. Cell lysates and 10-fold concentrated conditioned media were subjected to anti-KIAA1199 immunoprecipitation and NuPAGE 6%
Tris–glycine gels and detected by autoradiography. (E) Deglycosylation of KIAA1199-V5. The lysate and 5-fold concentrated conditioned media of KIAA1199-V5 transfectants
were treated with N-glycanase or Endo H and then subjected to immunoblotting with anti-KIAA1199 antibody. (F) N-terminal amino acid sequence of KIAA1199-V5 secreted
into conditioned media. The actual N-terminal protein sequence obtained is underlined. (G) Binding of secreted KIAA1199-V5 to HA. Conditioned media of KIAA1199-V5
transfectants were incubated with H2O (negative control) or HA. The samples were precipitated with CPC and subjected to immunoblotting with anti-KIAA1199 antibody.
H. Yoshida et al. / FEBS Letters 588 (2014) 111–116 115KIAA1199-V5 transfectants and Detroit 551 skin ﬁbroblasts was
not precipitated after ultracentrifugation at 100000g for 1 h (data
not shown), suggesting that secretion of KIAA1199 from these cells
is unlikely to involve exosome-dependent pathway. Importantly,
the observations in which secreted mature-form KIAA1199
showed no HA degrading activity support the idea that
KIAA1199-mediated HA depolymerization occurs through rapid
vesicle endocytosis [6]. On the other hand, the ﬁnding that se-
creted KIAA1199 had an HA-binding capability may reﬂect the
need for a speciﬁc condition and/or interaction with other mole-
cules to show the activity extracellularly, or another potential role
of the protein apart from HA degradation. However, further
detailed studies are necessary to better understand the roles of
secreted KIAA1199. Because of the biological and therapeutic
signiﬁcance of KIAA1199 in HA catabolism in healthy skin [6], a
major determinant organ for total body HA turnover [1], and in
the KIAA1199-linked diseases such as arthritis, cancers, hearing
loss, and Werner syndrome [6,7,12,13], further study to clarify
the molecular mechanism underlying post-translational matura-
tion and spatial regulation for the functional expression of
KIAA1199, as well as its expressional regulation at the transcrip-
tion level, would be of importance.Acknowledgement
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